In brief, this study reveals that MST1 markedly reduces the accumulation of FC in the liver by activating the AMPK/SREBP2 signaling axis, thereby effectively impeding the pathological progression of NASH. Here, MST1 is linked to metabolic dysfunction-associated steatohepatitis.